A
Amanda L. Christie
Researcher at Harvard University
Publications - 50
Citations - 7580
Amanda L. Christie is an academic researcher from Harvard University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 29, co-authored 49 publications receiving 6415 citations. Previous affiliations of Amanda L. Christie include AstraZeneca & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Mechanisms of lymphoma clearance induced by high-dose alkylating agents
Chen Lossos,Yunpeng Liu,Yunpeng Liu,Kellie E. Kolb,Kellie E. Kolb,Kellie E. Kolb,Amanda L. Christie,Alexandria Van Scoyk,Sanjay M. Prakadan,Sanjay M. Prakadan,Sanjay M. Prakadan,Kay Shigemori,Kristen E. Stevenson,Sara N. Morrow,Olivia Plana,Cameron Fraser,Kristen L Jones,Huiyun Liu,Christian P. Pallasch,Rebecca Modiste,Quang-Dé Nguyen,Jeffrey W. Craig,Elizabeth A. Morgan,Francisco Vega,Jon C. Aster,Kristopher A. Sarosiek,Alex K. Shalek,Alex K. Shalek,Alex K. Shalek,Michael T. Hemann,Michael T. Hemann,David M. Weinstock +31 more
TL;DR: It is shown that antibody resistance within the bone marrow (BM) is not present upon early engraftment but develops during lymphoma progression, and a novel mechanism through which high-dose alkylating agents promote macrophage-dependent lymphoma clearance is defined.
Journal ArticleDOI
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Atsushi Nonami,Martin Sattler,Ellen Weisberg,Qingsong Liu,Jianming Zhang,Matthew P. Patricelli,Amanda L. Christie,Amy Saur,Nancy E. Kohl,Andrew L. Kung,Hojong Yoon,Taebo Sim,Taebo Sim,Nathanael S. Gray,James D. Griffin +14 more
TL;DR: It is suggested that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes, and one of the compounds identified, GNF-7, potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous leukemia and acute lymphoblastic leukemia.
Journal ArticleDOI
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
Elena Battistello,Elena Battistello,Elena Battistello,Natalya Katanayeva,Elie Dheilly,Daniele Tavernari,Daniele Tavernari,Maria C. Donaldson,Luca Bonsignore,Margot Thome,Amanda L. Christie,Mark A. Murakami,Olivier Michielin,Olivier Michielin,Olivier Michielin,Giovanni Ciriello,Giovanni Ciriello,Vincent Zoete,Vincent Zoete,Vincent Zoete,Elisa Oricchio +20 more
TL;DR: To completely ablate the activity of the BCR, the SRC kinases LYN, FYN, and BLK are repressed, which reduced tumor growth in xenografts and cell lines derived from patients with DLBCL independent of their molecular subtype.
Journal ArticleDOI
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Ellen Weisberg,Alexandre Puissant,Richard Stone,Martin Sattler,Sara J. Buhrlage,Jing Yang,Paul W. Manley,Chengcheng Meng,Michael J Buonopane,John F. Daley,Suzan Lazo,Renee Wright,David M. Weinstock,Amanda L. Christie,Kimberly Stegmaier,James D. Griffin +15 more
TL;DR: Midostaurin and other dual FLT3/SYK inhibitors display superior anti-proliferative activity when compared to targeted FLT 3 inhibitors, such as crenolanib and quizartinib, against cells co-expressingFLT3-ITD and constitutively activated SYK-TEL.
Journal ArticleDOI
Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models
Afshin Beheshti,Afshin Beheshti,Afshin Beheshti,Kristen E. Stevenson,Charles R. Vanderburg,Charles R. Vanderburg,Dashnamoorthy Ravi,J. Tyson McDonald,Amanda L. Christie,Kay Shigemori,Hallie Jester,David M. Weinstock,Andrew M. Evens +12 more
TL;DR: In this article, a 10-miRNA signature (miR-15a, let-7c, let7b, miR-27a, MIR-10b, MIRA-18a, miRNA-24, and miR15a) was found in the serum of 86 DLBCL patients.